Protein Phosphatase PP5 Controls Bone Mass and the Negative Effects of Rosiglitazone on Bone through Reciprocal Regulation of PPAR gamma (Peroxisome Proliferator-activated Receptor gamma) and RUNX2 (Runt-related Transcription Factor 2) (Retracted article. See vol. 293, pg. 8314, 2018) Article (Web of Science)

cited authors

  • Stechschulte, Lance A.; Ge, Chunxi; Hinds, Terry D.; Sanchez, Edwin R.; Franceschi, Renny T.; Lecka-Czernik, Beata

authors

publication date

  • November 18, 2016

webpage

published in

category

start page

  • 24475

end page

  • 24486

volume

  • 291

issue

  • 47